Astria Therapeutics to Present Navenibart Data at C1 Inhibitor Deficiency and Angioedema Workshop

Astria Therapeutics announced that it will present safety and efficacy data from Phase 1a and 1b/2 clinical trials of navenibart, a monoclonal antibod...
Home/KnloSights/Clinical Trial Updates/Astria Therapeutics to Present Navenibart Data at C1 Inhibitor Deficiency and Angioedema Workshop